NEW YORK, Aug. 26, 2021 (News) — Cellectis S.A. (NASDAQ: CLLS – EURONEXT Progress: ALCLS) (the “Company”), a gene-modifying platform firm with scientific-stage immuno-oncology plans making use of allogeneic chimeric antigen receptor (Vehicle)-T cells and gene remedy courses for monogenic diseases, now declared that management plans to take part in five virtual investor conferences.
11th Annual Biotech Symposium (Goldman Sachs) Day: Tuesday, September 7, 2021Time: 8AM-6PM (GMT)
Citi’s 16th Yearly Biopharma Convention 2021Day: Thursday, September 9, 2021Time: 10:40AM ET
Wells Fargo Healthcare Convention Day: Friday, September 10, 2021Time: 9:20AM ET
H.C. Wainwright 23rd Yearly World Investment Meeting Day: Monday, September 13, 2021Time: 7AM ET
Baird 2021 International Health care Meeting Day: Wednesday, September 15, 2021Time: 9:05 AM ET
Live webcasts of these situations and a replay of these webcasts will be available below the “Events and Webcasts” area on the Investor webpage of the of the Company’s at web site: www.cellectis.com/en/buyers/functions-and-webcasts/
About CellectisCellectis is a gene enhancing business, building initial of its type therapeutic item candidates. Cellecties utilizes an allogeneic technique for Auto-T immunotherapies in oncology, pioneering the principle of off-the-shelf and all set-to-use gene-edited Auto T-cells to treat cancer clients, and a system to make therapeutic gene enhancing in hematopeitic stem cells for different ailments. As a medical-phase biopharmaceutical corporation with around 21 many years of skills in gene editing, Cellectis is acquiring lifetime-altering product or service candidates making use of TALEN®, its gene enhancing technology, and PulseAgile, its pioneering electroporation method to harness the ability of the immune method in order to take care of conditions with unmet healthcare wants.
As element of its commitment to a remedy, Cellectis stays committed to its target of delivering existence-saving UCART item candidates for various cancers like r/r AML), r/r B-ALL and r/r MM. .Mend is a new platform concentrating on hematopeitic stem cells to take care of blood diseases, immunodeficiencies and lysosomial storage ailments.
Cellectis headquarters are in Paris, France, with destinations in New York, New York and Raleigh, North Carolina. Cellectis is mentioned on the Nasdaq World wide Market place (ticker: CLLS) and on Euronext Development (ticker: ALCLS). For much more details, visit www.cellectis.com. Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.TALEN® is a registered trademark owned by Cellectis.
For even more information, remember to make contact with:
Media contacts:Pascalyne Wilson, Director, Communications, +33 7 76 99 14 33, pascalyne.wilson@cellectis.com Margaret Gandolfo, Senior Manager, Communications, 646-628-0300, margaret.gandolfo@cellectis.com Sheryl Seapy, True Chemistry, 213-262-9390, sseapy@realchemistry.com
IR contact:Eric Dutang, Main Monetary Officer, 646-630-1748, eric.dutang@cellectis.com
DisclaimerThis presentation incorporates “forward-looking” statements in the this means of relevant securities regulations, which includes the Non-public Securities Litigation Reform Act of 1995. Ahead-searching statements may perhaps be determined by words and phrases this kind of as “ “believe,” “expect,” “plan,” “designed to,” “foresee”, “look forward,” “will,” “could,” “would” or the damaging of these and very similar expressions. These forward-seeking statements, which are primarily based on our management’s current expectations and assumptions and on info presently readily available to management, involve statements about our investigate and advancement assignments and priorities, our pre-medical undertaking growth initiatives, the timing and progress of scientific trials (like with respect to patient enrollment and observe-up), the timing of our presentation of medical facts, the adequacy of our supply of clinical vials, the timing of completion of construction of our Raleigh, North Carolina producing facility, operational capabilities at our production services, the sufficiency of hard cash to fund our functions. These forward-seeking statements are designed in light of info at this time readily available to us and are subject to many risks and uncertainties, which includes with regard to the various hazards linked with biopharmaceutical item applicant advancement as properly as the duration and severity of the COVID-19 pandemic and governmental and regulatory steps carried out in response to the evolving scenario. With respect to our funds runway, our working programs, such as products improvement programs, may possibly transform as a result of various variables, which includes things now unknown to us. Furthermore, lots of other significant things, which includes all those explained in our Once-a-year Report on Form 20-F and the money report (including the administration report) for the 12 months finished December 31, 2020 and subsequent filings Cellectis makes with the Securities Exchange Fee from time to time, as very well as other recognized and unknown pitfalls and uncertainties might adversely influence this sort of ahead-looking statements and result in our true outcomes, performance or achievements to be materially diverse from individuals expressed or implied by the ahead-hunting statements. Except as required by law, we assume no obligation to update these ahead-hunting statements publicly, or to update the reasons why real success could vary materially from all those predicted in the forward-wanting statements, even if new details gets to be obtainable in the foreseeable future.
- 2021_08_24_ September buyers conferences_Last
News Highlights
Read more here: Source link